Business
Director Declaration Sale of Shares
Director Declaration Sale of Shares.
About this update from Nanoco Group Plc
[{"type":"text","content":"\n \n\n\n\n Evolutec Group plc\n (\"Evolutec\" or \"the Company\")\n\nPursuant to rule 17 of AIM Regulations (Schedule 5), Dr David Philip\nBloxham (Chairman) disclosed on 17 March 2008 that on the same date\nhe sold 33,036 Ordinary 10p Shares in Evolutec Group plc at a price\nof 18p per share. The beneficial owner of the shares was the David\nPhilip Bloxham SIPP. After this transaction Dr Bloxham holds 103,472\nOrdinary Shares in the Company.\n\n17 April 2008\n\nEvolutec is listed on the AIM market of the London Stock Exchange and\ndeveloped therapeutics originally isolated from the saliva of ticks.\nFollowing the unsuccessful outcome of Phase II clinical trials on its\nlead clinical trail candidate, the Company licensed its intellectual\nproperty to third parties and is now focussing all its activities on\nthe identification of a single investment opportunity. This will\ntake advantage of Evolutec's AIM listing and its cash and cash\nequivalent reserve.\n\nSafe Harbour statement: this news release may contain forward-looking\nstatements that reflect the current expectations of the Company\nregarding future events. Forward-looking statements involve risks and\nuncertainties. Actual events could differ materially from those\nprojected herein and depend on a number of factors including the\nsuccess of the Company's strategy, the successful integration of\ncompleted mergers and acquisitions and achievement of expected\nsynergies from such transactions, and the ability of the Company to\nidentify and consummate suitable strategic and business combination\ntransactions.\n\n---END OF MESSAGE---\n\n\n\n\n\n\n\n\n \n ","length":1773,"tagName":"div"}]